PI3K/Akt/mTOR Signaling
- Akt(129)
- AMPK(75)
- CK2(11)
- DNA-PK(25)
- GSK-3(76)
- MELK(7)
- mTOR(118)
- PI3K(227)
- PI4K(15)
- PDK-1(18)
- PIKfyve(4)
- PKB(1)
- S6 Kinase(12)
Products for PI3K/Akt/mTOR Signaling
- Cat.No. Product Name Information
-
GC17984
FPA 124
Akt/PKB inhibitor
- GC38551 FPA-124
- GC17457 FRATide GSK-3 inhibitor
- GC33355 FT-1518 FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.
-
GC61855
Galegine hydrochloride
Galegine hydrochloride, a guanidine derivative, contributes to weight loss in mice.
- GC17967 GDC-0032 GDC-0032 (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with Kis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.
- GC11214 GDC-0068 (RG7440)
- GC32710 GDC-0077 (RG6114) GDC-0077 (RG6114) is a potent, orally available, and selective PI3Kα inhibitor (IC50=0.038 nM). GDC-0077 (RG6114) exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. GDC-0077 (RG6114) is more selective for mutant versus wild-type PI3Kα.
- GC10228 GDC-0084 PI3K and mTOR inhibitor, brain-permeable
- GC19161 GDC-0326 GDC-0326 is a potent and selective PI3Kα inhibitor with a Ki of 0.2 nM.
- GC12021 GDC-0349 MTOR inhibitor
- GC16154 GDC-0941 dimethanesulfonate A pan inhibitor of class I PI3K isoforms
- GC11177 GDC-0980 (RG7422) GDC-0980 (RG7422) (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with aKiof 17 nM for mTOR.
- GC10900 GDC-mTOR inhibitor
- GC64778 Gilmelisib Gilmelisib is an antineoplastic. Gilmelisib is a PI3K inhibitor (IC50 <1 nM for PI3K p110α) extracted from WO2017101847 A1, compound 1.
- GN10473 Ginkgolide C
- GN10584 Ginsenoside Rk1
- GC38606 Glaucocalyxin A Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect.
- GC17338 GNE-317 potent, brain-penetrant PI3K inhibitor
- GC10340 GNE-477 dual PI3K/mTOR inhibitor
- GC68429 GNE-490
- GC15423 GNE-493 Pan-PI3K/mTOR inhibitor
- GC38787 GNF4877 GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC50s of 6?nM and 16?nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC50 of 0.66?μM for mouse β (R7T1) cells).
- GC36178 Gomisin J A lignan with diverse biological activities
- GC36186 GS-9901 GS-9901 is a highly selective and orally active PI3Kδ inhibitor, with an IC50 of 1 nM.
- GC36190 GSK-3 inhibitor 1 GSK-3 inhibitor 1 is an inhibitor of GSK-3.
- GC14987 GSK-3 Inhibitor IX (BIO) GSK-3 Inhibitor IX (BIO) (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
- GC36193 GSK-3β inhibitor 1 GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM.
- GC66032 GSK-3β inhibitor 11 GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research.
- GC62338 GSK-3β inhibitor 3 GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia.
- GC62423 GSK-3/CDK5/CDK2-IN-1 GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a.
- GC16187 GSK-3β Inhibitor II GSK-3β inhibitor
- GC65309 GSK-F1 GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively.
- GC11018 GSK1059615 PI3K and mTOR inhibitor,potent and reversible
- GC33135 GSK2110183 GSK2110183 is the structural analogue of GSK2110183.
- GC33010 GSK2110183 hydrochloride GSK2110183 hydrochloride is the structural analogue of GSK2110183.
- GC15072 GSK2126458 GSK2126458 (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. GSK2126458 has anti-cancer activity.
- GC12305 GSK2141795 GSK2141795 (GSK2141795) is a potent and selective pan-Akt inhibitor with IC50 values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.
- GC15595 GSK2269557 inhibitor of PI3Kδ
- GC15679 GSK2292767 PI3Kδ inhibitor,potent and selective
- GC12275 GSK2334470 PDK1 inhibitor,highly specific and potent
- GC64612 GSK251 GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of PI3Kδ with a novel binding mode.
-
GC17109
GSK2636771
GSK2636771 is a potent adenosine triphosphate competitive oral inhibitor of PI3Kβ, with an IC50 of 5.
- GC43790 GSK3 Inhibitor XIII GSK3 Inhibitor XIII is an aminopyrazole ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK3), with 34% inhibition when used at a concentration of 2.5 μM.
- GC66035 GSK3-IN-1 GSK3-IN-1 (compound 11) is a GSK-3 inhibitor with an IC50 value of 12 μM. GSK3-IN-1 can be used in the research of diabetes.
- GC18810 GSK3β Inhibitor XI GSK3β inhibitor XI is a potent inhibitor of glycogen synthase kinase 3β (GSK3β; Ki = 25 nM).
- GC11724 GSK621 AMPK agonist
-
GC13696
GSK690693
GSK690693 is an ATP-competitive, low nanomolar inhibitor of Akt kinases with IC50 values of 2, 13, and 9 nM for Akt1, 2, and 3, respectively.
- GC17658 Guggulsterone Broad spectrum steroid receptor ligand
- GA10282 H-Leu-OH
- GC65460 HDACs/mTOR Inhibitor 1 HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo.
- GC38088 Hederacolchiside A1
- GC39266 Hematein Hematein is a oxidation product of hematoxylin acted as a dye. Hematein is an allosteric casein kinase II inhibitor with an IC50 of 0.74 μM. Hematein inhibits Akt/PKB Ser129 phosphorylation, the Wnt/TCF pathway and increases apoptosis in lung cancer cells.
- GC38168 Heterophyllin B Heterophyllin B is an active cyclic peptide isolated from Pseudostellaria heterophylla. Heterophyllin B provides a novel strategy for the treatment of esophageal cancer.
- GC64035 Hirsutenone Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects.
- GN10664 Honokiol
- GC16713 HS-173 novel PI3K inhibitor
- GC62572 hSMG-1 inhibitor 11e hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of 900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM).
- GC61925 hSMG-1 inhibitor 11j hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer.
- GC13185 HTH-01-015 NUAK1 inhibitor,highly specific and selective
- GC15540 IC-87114 PI3Kδ inhibitor
- GC62465 Idelalisib D5 Idelalisib D5 is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor.
- GC63017 IHMT-PI3Kδ-372 IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC50 of 14 nM.
- GC19411 IITZ-01 IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ.
- GC16617 IM-12 GSK-3β inhibitor, potent
- GC13503 iMDK PI3K and endogenous midkine (MDK) expression inhibitor
- GC62376 iMDK quarterhydrate iMDK quarterhydrate is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice.
-
GC10576
Imeglimin
Antidiabetic agent
- GC10956 Imeglimin hydrochloride Antidiabetic agent
- GC12975 Indirubin A cyclin-dependent kinases and GSK-3β inhibitor
- GC12661 Indirubin-3'-oxime Indirubin-3'-oxime is a potent GSK-3β inhibitor, and weakly inhibits 5-Lipoxygenase, with IC50s of 22 nM and 7.8-10 μM, respectively; Indirubin-3'-oxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC50s of 100 and 180 nM.
- GC36312 Indirubin-3'-monoxime-5-sulphonic acid Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of CDK1, CDK5, and GSK-3β with IC50s of 5 nM, 7 nM, and 80 nM, respectively.
- GC36313 Indirubin-5-sulfonate Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively. Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β.
- GC10969 INK 128(MLN0128) INK 128 (MLN0128) (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
- GC12416 INK1117 INK1117 (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM.
- GC65559 INY-03-041 INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor GDC-0068 conjugated to Lenalidomide (Cereblon ligand). INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0 nM, 6.8 nM and 3.5 nM, respectively.
- GC32794 Ipatasertib dihydrochloride (GDC-0068 (dihydrochloride)) Ipatasertib dihydrochloride (GDC-0068 (dihydrochloride)) (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.
- GC10749 IPI-145 (INK1197) IPI-145 (INK1197) (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.
- GC31756 IPI-3063 IPI-3063 is a potent and selective PI3K p110δ inhibitor with an IC50 of 2.5?±?1.2 nM.
- GC19202 IPI549 IPI549 (IPI549) is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM. IPI549 shows >100-fold selectivity over other lipid and protein kinases.
- GC13795 Isobavachalcone A chalcone and flavonoid with diverse biological activities
- GN10023 Isorhamnetin
- GC32995 JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.
- GC34909 JR-AB2-011 A selective mTORC2 inhibitor
- GC33357 K-80003 (TX-803) K-80003 (TX-803) is a potent inhibitor of tRXRα-dependent Akt activation and cancer cell growth.
- GC48507 Kaempferol 3-O-galactoside Kaempferol 3-O-galactoside (Trifolin) is a derivative of flavonoid, which is isolated from the aerial part of Consolida oliveriana.
- GC38209 Kahweol A natural diterpene with antiinflammatory and antiangiogenic properties
- GC63934 Karanjin Karanjin is a major active furanoflavonol constituent of Fordia cauliflora. Karanjin induces GLUT4 translocation in skeletal muscle cells by increasing AMPK activity. Karanjin can induce cancer cell death through cell cycle arrest and enhance apoptosis.
- GC32118 KDU691 An antimalarial compound
- GC38033 KDU731 KDU731, an orally active C.
- GC14182 Kenpaullone CDK1/cyclin B and GSK-3β inhibitor
- GC15553 KP372-1 specific Akt inhibitor
- GC14346 KU-0060648 Dual DNA-PK/PI3-K inhibitor, ATP-competitive
- GC15167 KU-0063794 MTORC1 and mTORC2 inhibitor
- GC68037 L-Leucine-1-13C,15N
- GC68219 L-Leucine-13C
- GC63833 L-Leucine-15N
- GC66357 L-Leucine-d2 L-Leucine-d2 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.
- GC64188 L-Leucine-d3 L-Leucine-d3 is the deuterium labeled L-Leucine.
- GC10573 L803-mts Selective peptide inhibitor of glycogen synthase kinase-3 (GSK-3)